Semaglutide vs Tirzepatide: Which GLP-1 Is Right for You?
A detailed comparison of semaglutide and tirzepatide — mechanism, dose, half-life, weight-loss data, and which to choose by goal. Based on Grade A+ clinical trial evidence.
Semaglutide and Tirzepatide are both once-weekly injectable GLP-1 receptor agonists with the strongest fat-loss evidence available — but they aren't equivalent. Tirzepatide adds GIP receptor activation (dual agonism), which consistently produces greater weight loss than semaglutide alone. The choice between them comes down to how much fat loss you need, your cardiovascular history, and how much long-term safety data matters to you.
Head-to-Head Comparison
| Factor | Semaglutide | Tirzepatide |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | Dual GLP-1 + GIP agonist |
| Evidence Grade | A+ (STEP trials) | A+ (SURMOUNT trials) |
| Mean weight loss (max dose) | ~15% body weight | 15–23% body weight |
| Half-life | ~7 days | ~5 days |
| Dosing frequency | Once weekly | Once weekly |
| Dose range | 0.25–2.4 mg/week | 2.5–15 mg/week |
| FDA approval | 2017 (Ozempic); 2021 (Wegovy) | 2022 (Mounjaro); 2023 (Zepbound) |
| Cardiovascular outcomes trial | SELECT trial completed (positive) | SURPASS-CVOT ongoing |
| Nausea profile | Common during titration | Similar; may be slightly less |
| Post-market safety record | 7+ years | 3+ years |
The GIP Receptor Difference
GIP (glucose-dependent insulinotropic peptide) and GLP-1 are both incretin hormones released after meals, but they engage different pathways. GIP activates receptors in the hypothalamus, adipose tissue, bone, and gut. Tirzepatide's GIP activation adds appetite suppression through a distinct hypothalamic circuit and may improve the adipose tissue's response to insulin more directly than GLP-1 alone. This appears to explain the incremental weight loss advantage — it's not just stronger GLP-1 activity, it's a genuinely different second mechanism.
Choose by Goal
Choose Tirzepatide if…
- Maximum fat loss is the priority
- You've plateaued on semaglutide
- You have significant insulin resistance
- HbA1c reduction is a goal alongside weight
Choose Semaglutide if…
- You want the longest safety track record
- Proven cardiovascular outcomes matter (SELECT trial)
- You're starting your first GLP-1 therapy
- Lower starting cost is a factor
Frequently Asked Questions
Is tirzepatide just a stronger version of semaglutide?
Not exactly — it has a different mechanism. It's not "more semaglutide"; it's semaglutide-like GLP-1 action plus a second distinct mechanism through the GIP receptor. The weight loss advantage isn't just higher receptor activation — it's activation of a second pathway that semaglutide doesn't touch at all.
Can I switch from semaglutide to tirzepatide?
Yes — switching is common when someone plateaus on semaglutide at maximum dose. Typically you stop semaglutide and start tirzepatide at a low dose (2.5 mg/week), titrating up gradually. The GLP-1 receptor overlap means some cross-tolerance exists, but the GIP component is new stimulation. Always do this under physician supervision.
Do they have the same side effects?
Largely yes — nausea, vomiting, constipation, and diarrhea are the most common with both compounds. The thyroid C-cell and pancreatitis contraindications are shared class effects. Tirzepatide may have slightly fewer GI side effects at equivalent weight-loss doses in some studies, but the difference is not dramatic. Slow titration mitigates GI side effects for both.
Will muscle mass be preserved on tirzepatide versus semaglutide?
Both GLP-1 agonists cause some lean mass loss alongside fat loss — the ratio in trials is roughly 60–70% fat / 30–40% lean mass without resistance training. Tirzepatide may preserve lean mass slightly better due to the GIP mechanism, but the practical difference is modest. Resistance training during treatment is more impactful than the drug choice for lean mass preservation.
What happens to weight when you stop either drug?
Weight regain after stopping is well-documented for both compounds. STEP 4 (semaglutide) showed ~66% of weight loss was regained within 2 years off-drug when lifestyle interventions weren't maintained. Tirzepatide shows similar patterns. This is a chronic medication for a chronic condition — stopping without sustained lifestyle change typically leads to regain regardless of which compound was used.
GLP-1 Protocol Questions?
Join Hacksmith's Peptalk for real-world GLP-1 protocol discussions, titration advice, and member experiences with both compounds.
Join the Community →FDA-approved forms require a prescription. Consult a qualified healthcare provider. Dosing figures are from clinical trial data — not prescriptions.